Search
Fosdenopterin
go.drugbank.com/drugs/DB16628Approved[A230088] Signs and symptoms begin shortly after birth and are caused by a build-up of toxic sulfites resulting from a lack of SOX activity. … In 2009 a recombinant, E. coli-produced cPMP was granted orphan drug designation by the FDA, becoming the first therapeutic option for patients with MoCD type A.
ING-1
go.drugbank.com/drugs/DB05831InvestigationalIt is an attractive target for immunotherapy. … ING-1 is a high-affinity, human engineered trade mark monoclonal antibody that recognizes a 40 kilodalton epithelial cell adhesion molecule (EpCAM) glycoprotein that is expressed in high levels on most
AMT-080
go.drugbank.com/drugs/DB17846ExperimentalAMT-080 is an investigational gene therapy being investigated for the treatment of Duchenne muscular dystrophy.
Benzophenone
go.drugbank.com/drugs/DB01878ApprovedSubstituted benzophenones such as oxybenzone and dioxybenzone are used in sunscreen.
Pentolinium
go.drugbank.com/drugs/DB01090ApprovedPentolinium is a nicotinic antagonist that has been used as a ganglionic blocking agent in hypertension.
Brifentanil
go.drugbank.com/drugs/DB09172ExperimentalIllicitBrifentanil (also known as A-3331) is an analog of fentanyl, a potent opioid. This drug is classified as an opioid analgesic and was developed in the early 1990s.
Gadoteric acid
go.drugbank.com/drugs/DB09132ApprovedInvestigationaldue to a decreased tendency of gadolinium dechelation. … Gadoteric acid, commonly used in the salt form gadoterate meglumine, is a macrocyclic, ionic gadolinium-based contrast agent (GBCA).
Categories: Compounds used in a research, industrial, or household settingVSF-173
go.drugbank.com/drugs/DB05753InvestigationalVSF-173 is an oral small molecule. It is an oral compound that has demonstrated effects on animal sleep/wake patterns and gene expression patterns suggestive of a stimulant effect. … It is developed for the treatment of excessive sleepiness. Study shows that VSF-173 possesses a novel mechanism to address disorders of excessive sleepiness.
Vimseltinib
go.drugbank.com/drugs/DB17520ApprovedInvestigational[L52230] It is highly selective, with a >500-fold selectivity for CSF1R over its nearest off-target kinase. … [A265035] It is intended to provide a safer alternative to [pexidartinib], a previously approved CSF1R inhibitor associated with significant liver toxicity - the greater selectivity of vimseltinib results
Deudextromethorphan
go.drugbank.com/drugs/DB19054InvestigationalDeudextromethorphan is under investigation in clinical trial NCT02153502 (Efficacy, Safety, and Tolerability Study of AVP-786 as an Adjunctive Therapy in Patients With Major Depressive Disorder With an